Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

Next Previous
X
Search
Trial Profile

Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clopidogrel (Primary) ; Aspirin
  • Indications Myocardial infarction; Stroke; Transient ischaemic attacks
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms POINT

    • Most Recent Events

    • 04 Jan 2024 Results of post hoc secondary analysis determining how baseline stroke risk modified the efficacy of clopidogrel-aspirin for transient ischemic attack and minor ischemic stroke, published in the Stroke
    • 26 Apr 2022 Results identifying predictors of very early stroke recurrence, presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 11 Feb 2022 Results of post-hoc analysis assessing effect of smoking status on subsequent stroke risk in patients with minor ischemic stroke or TIA and determine whether smoking improves the effect of clopidogrel treatment on subsequent stroke risk reduction presented at the International Stroke Conference 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top